MX2018016364A - Anticuerpos anti-pd-l1. - Google Patents

Anticuerpos anti-pd-l1.

Info

Publication number
MX2018016364A
MX2018016364A MX2018016364A MX2018016364A MX2018016364A MX 2018016364 A MX2018016364 A MX 2018016364A MX 2018016364 A MX2018016364 A MX 2018016364A MX 2018016364 A MX2018016364 A MX 2018016364A MX 2018016364 A MX2018016364 A MX 2018016364A
Authority
MX
Mexico
Prior art keywords
antibodies
immunocytokines
present
bispecific antibodies
cytokine
Prior art date
Application number
MX2018016364A
Other languages
English (en)
Spanish (es)
Inventor
CAMPBELL Jaime
Sandy Nikole
Van Krinks Cassandra
John Arkinstall Stephen
Germaschewski Volker
Kirby Ian
KOSMAC Miha
Gallagher Thomas
Deantonio Cecilia
Douglas Gillies Stephen
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/211,504 external-priority patent/US9567399B1/en
Priority claimed from GBGB1615224.1A external-priority patent/GB201615224D0/en
Priority claimed from GBGB1615335.5A external-priority patent/GB201615335D0/en
Priority claimed from GBGB1620414.1A external-priority patent/GB201620414D0/en
Priority claimed from GBGB1621782.0A external-priority patent/GB201621782D0/en
Priority claimed from GBGB1702338.3A external-priority patent/GB201702338D0/en
Priority claimed from GBGB1702339.1A external-priority patent/GB201702339D0/en
Priority claimed from GBGB1703071.9A external-priority patent/GB201703071D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2018016364A publication Critical patent/MX2018016364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
MX2018016364A 2016-06-20 2017-06-20 Anticuerpos anti-pd-l1. MX2018016364A (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662352291P 2016-06-20 2016-06-20
US15/211,504 US9567399B1 (en) 2016-06-20 2016-07-15 Antibodies and immunocytokines
GB201613683 2016-08-09
GBGB1615224.1A GB201615224D0 (en) 2016-09-07 2016-09-07 Antibodies
GBGB1615335.5A GB201615335D0 (en) 2016-09-09 2016-09-09 Antibodies and immunocytokines
US15/354,971 US9617338B1 (en) 2016-06-20 2016-11-17 Antibodies and immunocytokines
GBGB1620414.1A GB201620414D0 (en) 2016-12-01 2016-12-01 Antibodies
GBGB1621782.0A GB201621782D0 (en) 2016-12-20 2016-12-20 Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines
GBGB1702338.3A GB201702338D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines
GBGB1703071.9A GB201703071D0 (en) 2017-02-24 2017-02-24 Antibodies
US15/480,525 US10604576B2 (en) 2016-06-20 2017-04-06 Antibodies and immunocytokines
PCT/GB2017/051796 WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies

Publications (1)

Publication Number Publication Date
MX2018016364A true MX2018016364A (es) 2019-11-28

Family

ID=59713385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016364A MX2018016364A (es) 2016-06-20 2017-06-20 Anticuerpos anti-pd-l1.

Country Status (16)

Country Link
US (4) US12209128B2 (OSRAM)
EP (2) EP3471754A1 (OSRAM)
JP (5) JP7461741B2 (OSRAM)
KR (2) KR102531889B1 (OSRAM)
CN (3) CN116903741A (OSRAM)
AU (1) AU2017281830B2 (OSRAM)
BR (2) BR112018076281A2 (OSRAM)
CA (2) CA3026474A1 (OSRAM)
IL (1) IL263834B2 (OSRAM)
MX (1) MX2018016364A (OSRAM)
NZ (2) NZ748710A (OSRAM)
RU (2) RU2756236C2 (OSRAM)
SG (1) SG11201810509PA (OSRAM)
TW (4) TW201803905A (OSRAM)
WO (3) WO2017220989A1 (OSRAM)
ZA (1) ZA201900353B (OSRAM)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
KR20230044038A (ko) * 2016-08-09 2023-03-31 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20230073346A (ko) 2016-11-28 2023-05-25 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
WO2019107380A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
MX2020005160A (es) 2017-11-28 2020-08-20 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CA3082975A1 (en) * 2018-01-25 2019-08-19 I-Mab Biopharma Us Limited Anti-pd-l1 antibody and il-7 fusions
BR112020015994A2 (pt) * 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3092108A1 (en) * 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3762406A2 (en) 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019241707A1 (en) * 2018-06-14 2019-12-19 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition antibody-mediated target cytosis
US11001635B2 (en) * 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CN110790839B (zh) * 2018-08-03 2023-05-12 江苏恒瑞医药股份有限公司 抗pd-1抗体、其抗原结合片段及医药用途
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
HUE068059T2 (hu) * 2018-09-17 2024-12-28 Gi Innovation Inc Il-2 fehérjét és CD80 fehérjét tartalmazó fúziós fehérje és annak felhasználása
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
TWI840433B (zh) * 2018-10-29 2024-05-01 大陸商北京強新生物科技有限公司 新穎合理設計的蛋白質組合物
CN119735694A (zh) * 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
TW202020159A (zh) * 2018-11-16 2020-06-01 大陸商南京金斯瑞生物科技有限公司 人源化抗人pd-l1單克隆抗體及其製備方法和用途
US12195538B2 (en) * 2018-11-30 2025-01-14 Abl Bio Inc. Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NEW IMMUNOSUPPRESSIVE INTERLEUKIN 2
KR20210142594A (ko) 2018-12-26 2021-11-25 시티 오브 호프 활성화 가능한 차폐된 항-ctla4 결합 단백질
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
KR20210145254A (ko) * 2019-03-29 2021-12-01 유니베르시태트 취리히 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
GB201905552D0 (en) * 2019-04-18 2019-06-05 Kymab Ltd Antagonists
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN110128550B (zh) * 2019-05-30 2023-01-13 南京惟亚德生物医药有限公司 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
AU2020291012B2 (en) 2019-06-12 2025-09-25 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
AU2020292421A1 (en) * 2019-06-14 2022-01-27 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
JP2022538008A (ja) * 2019-06-26 2022-08-31 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫エフェクター細胞をターゲット化して増殖させるための方法及び材料
US11725058B2 (en) 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
KR20220034133A (ko) * 2019-06-26 2022-03-17 더 존스 홉킨스 유니버시티 조절 t 세포의 표적화된 확장을 위한 방법 및 재료
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
BR112021016512A2 (pt) 2019-08-29 2022-03-15 Remegen Co Ltd Anticorpo anti pd-l1 e uso do mesmo
AU2020337999A1 (en) * 2019-08-30 2022-03-24 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment
US11680098B2 (en) * 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
CA3153785A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
EP4047021A4 (en) * 2019-10-17 2023-11-22 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC OX40/PD1-L1 ANTIBODIES
WO2021076865A1 (en) * 2019-10-18 2021-04-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN116057070A (zh) * 2019-10-23 2023-05-02 礼进生物医药科技（上海）有限公司 抗cd40结合分子和包括其的双特异性抗体
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4058478A4 (en) * 2019-11-14 2022-12-28 Academia Sinica USES OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY
KR102400884B1 (ko) * 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
AU2020387479B2 (en) * 2019-11-20 2024-06-06 Gi Cell, Inc. Composition for culturing regulatory T cells and use thereof
WO2021101270A1 (ko) 2019-11-20 2021-05-27 주식회사 지아이셀 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법
CN114829585B (zh) * 2019-11-20 2024-08-23 吉爱希公司 用于培养t细胞的组合物及使用其来培养t细胞的方法
BR112022010063A2 (pt) * 2019-11-27 2022-09-06 Gi Cell Inc Composição para tratamento anticâncer, compreendendo células nk e proteína de fusão que compreende proteína il-2 e proteína cd80
CN114786701A (zh) 2019-11-27 2022-07-22 Gi 医诺微新 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023509214A (ja) * 2020-01-10 2023-03-07 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｔｉｇｉｔ抗体、それを含む多重特異性抗体及びその使用方法
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
CN115943210A (zh) * 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
US11168128B2 (en) 2020-02-26 2021-11-09 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
EP4122953A4 (en) * 2020-03-18 2023-08-23 GI Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
GB202007099D0 (en) * 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230257438A1 (en) * 2020-06-30 2023-08-17 Gi Innovation, Inc. Fusion protein comprising anti-lag-3 antibody and il-2, and use thereof
CN113913379B (zh) * 2020-07-07 2024-02-06 深圳市菲鹏生物治疗股份有限公司 T淋巴细胞及其应用
BR112023001187A2 (pt) 2020-07-20 2023-04-04 Deka Biosciences Inc Proteínas de fusão de citocina dupla compreendendo il -10
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN111705038B (zh) * 2020-08-24 2020-11-03 江苏集萃药康生物科技有限公司 一种稳定表达人源pdl1/cd73蛋白细胞株的构建方法及其应用
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
TWI894360B (zh) * 2020-09-22 2025-08-21 大陸商南京聖和藥業股份有限公司 抗tigit抗體及雙抗體和它們的應用
US20220135684A1 (en) * 2020-10-14 2022-05-05 Xencor, Inc. Bispecific antibodies that bind pd-l1 and cd28
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
EP4281474A4 (en) * 2021-01-21 2025-03-05 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2024508658A (ja) 2021-02-04 2024-02-28 ジェヌーヴ インク． 抗ｐｄ－１抗体及びその用途
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240415884A1 (en) * 2022-02-01 2024-12-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Molecules that bind to cd276 polypeptides
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
KR20240166575A (ko) * 2022-04-02 2024-11-26 하버 바이오메드 (상하이) 컴퍼니 리미티드 Pd-l1 및 cd40을 표적화하는 항원 결합 단백질, 이의 제조 방법 및 응용
EP4507728A1 (en) * 2022-04-11 2025-02-19 Flagship Pioneering Innovations VII, LLC Compositions and methods
JPWO2023219147A1 (OSRAM) * 2022-05-13 2023-11-16
JP2025518785A (ja) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
JPWO2023238949A1 (OSRAM) 2022-06-10 2023-12-14
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
WO2024015733A1 (en) * 2022-07-13 2024-01-18 10X Genomics, Inc. Improved methods and systems for identification and characterization of antigen-binding molecules from single cells
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025006973A2 (en) * 2023-06-29 2025-01-02 Board Of Regents, The University Of Texas System Methods for treating immune related adverse events
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (818)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4663281A (en) 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0493418T3 (da) 1989-09-20 1997-11-03 Abbott Lab Fremgangsmåde til fremstilling af fusionsproteiner
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2077348A1 (en) 1990-03-02 1991-09-03 Stephen D. Gillies Antibody constructs with enhanced binding affinity
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
WO1992008801A1 (en) 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0694042B1 (en) 1993-03-25 2004-11-03 Merck & Co. Inc. Inhibitor of vascular endothelial cell growth factor
ATE255906T1 (de) 1993-10-01 2003-12-15 Immunex Corp Antikörper gegen cd40
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
ATE267607T1 (de) 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
USRE38313E1 (en) 1994-05-06 2003-11-11 Institut Gustave Roussy Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AU5265296A (en) 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
AU3457497A (en) 1996-06-17 1998-01-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel PTP20, PCP-2, BDP1, CLK and SIRP proteins and related products and method
AU3505397A (en) 1996-06-25 1998-01-14 Trustees Of The University Of Pennsylvania, The Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
NL1003648C2 (nl) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
JP2001501471A (ja) 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド 血管新生の阻害のための遺伝子治療
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US20070055056A1 (en) 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20060246483A1 (en) 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20060223088A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20070015696A1 (en) 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20060223090A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20080103090A1 (en) 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
NZ502052A (en) 1997-06-20 2001-01-26 Biogen Inc CD154 blockade therapy for pancreatic islet tissue transplantation
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
JP4463418B2 (ja) 1997-09-23 2010-05-19 ドイツ連邦共和国 Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE69833779T2 (de) 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
US6979547B2 (en) 1998-03-25 2005-12-27 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics, Inc. Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
EP1071468B1 (en) 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
MXPA00010151A (es) 1998-04-17 2002-08-06 Lexigen Pharm Corp Mejoramiento de las respuestas inmunes mediadas por proteina de fusion de anticuerpo-citocina mediante la soadministracion con inhibidores de prostaglandina.
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
AU4009899A (en) 1998-05-23 1999-12-13 Tanox, Inc. Molecules targeting cd40 and tumor cells
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
CA2335096A1 (en) 1998-07-16 2000-01-27 Hyseq, Inc. Methods and materials relating to novel cd39-like polypeptides
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
ES2342239T3 (es) 1998-08-25 2010-07-02 Merck Patent Gmbh Expresion y exportacion de angiostatina y de endostatina como inmunofusinas.
WO2000024869A2 (en) 1998-10-23 2000-05-04 Yale University Methods for modulating cell fusion
SG143018A1 (en) 1998-12-23 2008-06-27 Pfizer Human monoclonal antibodies to ctla-4
CZ20012406A3 (cs) 1999-01-07 2002-03-13 Lexigen Pharmaceuticals, Corp. Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
EP1156823B1 (en) 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (de) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
US20030119038A1 (en) 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
CA2388617A1 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20020081679A1 (en) 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
GB9927757D0 (en) 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
AU2841101A (en) 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
WO2001057081A2 (en) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
AU2001253496A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
JP2004515217A (ja) 2000-06-16 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
CA2417874C (en) 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
AU2001288286B2 (en) 2000-08-18 2007-05-10 The Regents Of The University Of California Methods for treating demyelinating diseases
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
AU2001296908A1 (en) 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002227280A1 (en) 2000-12-08 2002-06-18 Incyte Genomics, Inc. Protein modification and maintenance molecules
US20040198661A1 (en) 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
BR0116803A (pt) 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
KR20040074587A (ko) 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
EP1423134A2 (en) 2001-03-21 2004-06-02 Human Genome Sciences Human secreted proteins
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US20040023243A1 (en) 2001-06-13 2004-02-05 Yue Henry Proteases
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
CA2452544A1 (en) 2001-07-12 2003-01-23 The Regents Of The University Of California Method for treating secondary tissue degeneration associated with central nervous system injury
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
US20040038242A1 (en) 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
EP1441759A2 (de) 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002365814A1 (en) 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003209059A1 (en) 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
ES2559763T3 (es) 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2004029069A2 (en) 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
JP2006511620A (ja) 2002-12-05 2006-04-06 プロテイン デザイン ラブス インコーポレイティド 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
PT1572748E (pt) 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
AU2003299823A1 (en) 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
CA2517287C (en) 2003-02-28 2022-12-13 The Johns Hopkins University Regulation of t cells by lag-3 (cd223)
US20080019973A1 (en) 2003-03-17 2008-01-24 Lane Thomas E Methods for Treating Ocular Inflammation by Neutralizing Cxcl10 Activity
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
CA2522819A1 (en) 2003-04-22 2004-11-04 Immunomedics, Inc. Polyvalent protein complex
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
PL207804B1 (pl) 2003-07-29 2011-02-28 Htl Strefa Społka Z Ograniczoną Odpowiedzialnością Przyrząd do nakłuwania
AU2004260702A1 (en) 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US20050053600A1 (en) 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
CA2542037A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition of antibody capable of specifically binding ccr4
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
JP4765040B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 多発性骨髄腫の処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体の使用
SI1694360T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
JPWO2005053741A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
EP1708961B1 (en) 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
SI2383295T1 (sl) 2003-12-10 2015-07-31 E.R. Squibb & Sons, L.L.C. Protitelesa IP-10 in njihova uporaba
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
TW200540186A (en) 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2005219322B2 (en) 2004-03-09 2008-09-18 Kyoto University Pharmaceutical Composition Comprising CXCR3 Inhibitor
AU2005229009A1 (en) 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
US7998481B2 (en) 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
RU2006141632A (ru) 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005118635A2 (en) 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2006004716A2 (en) 2004-06-29 2006-01-12 The Johns Hopkins University Amelioration of drug-induced toxicity
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN101023102B (zh) 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
HUE039237T2 (hu) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-H1 és PD-1 vesesejt karcinoma kezelésében
WO2006039819A1 (en) 2004-10-15 2006-04-20 St. Michael's Hospital Markers of lung injury
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
CA2601936C (en) 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
CA2598452A1 (en) 2005-03-11 2006-09-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
MX2007011767A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
AR053690A1 (es) 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006118085A1 (ja) 2005-04-26 2006-11-09 Stelic Institute Of Regenerative Medicine 肝細胞複製促進剤およびインスリン抵抗性改善剤
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
RU2407544C2 (ru) 2005-05-26 2010-12-27 Сиэтл Дженетикс, Инк. Гуманизированные анти-cd40-антитела и способы их применения
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP1910828A4 (en) 2005-07-01 2012-03-14 Univ St Louis PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1904530A2 (en) 2005-07-07 2008-04-02 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
AU2006279658A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
GB0517487D0 (en) 2005-08-26 2005-10-05 Isis Innovation Antibodies
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
AU2006308860B2 (en) 2005-11-01 2012-01-12 Novartis Ag Uses of anti-CD40 antibodies
CA2628105A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AR057253A1 (es) 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
AU2007207764B2 (en) 2006-01-12 2012-06-07 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US20110086367A1 (en) 2006-04-03 2011-04-14 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
EP2019857B1 (en) 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP2348106B1 (en) 2006-05-08 2014-07-02 Adaerata, Limited Partnership Chimeric proteins, cells comprising same, and assays using same
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
KR101320916B1 (ko) 2006-05-11 2013-10-23 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
WO2008027338A2 (en) 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
ME02269B (me) 2006-10-02 2016-04-28 Medarex Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
US8178100B2 (en) 2006-10-13 2012-05-15 Seoul National University Industry Foundation Antibodies to IP-10 for treating bone diseases with bone destruction
JP2010013355A (ja) 2006-10-19 2010-01-21 Stelic Institute Of Regenerative Medicine 心筋障害抑制剤
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
WO2008050962A1 (en) 2006-10-24 2008-05-02 College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
US20100040610A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
EP2083859A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme PCSK9 ANTAGONISTS
AU2007322265B2 (en) 2006-11-07 2013-06-20 Merck Sharp & Dohme Corp. Antagonists of PCSK9
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
CL2007003291A1 (es) 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
TW200837080A (en) 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
CA2678626A1 (en) 2007-02-28 2008-09-04 Novimmune S.A. Anti-ip-10 antibodies and methods of use thereof
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
US20100233177A1 (en) 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
MX2009011226A (es) 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
WO2009009547A2 (en) 2007-07-09 2009-01-15 Qualcomm Incorporated Methods for sending small packets in a peer-to-peer (p2p) network
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
EP2178561A1 (en) 2007-07-25 2010-04-28 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
CN101802008B (zh) 2007-08-21 2015-04-01 安美基公司 人类c-fms抗原结合蛋白
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
EP2207797A4 (en) 2007-10-11 2010-12-22 Univ Health Network MODULATION OF THE SIRPALPHA CD47 INTERACTION TO IMPROVE TRANSPLANTATION OF HUMAN HEMATOPOETIC STEM CELLS AND COMPOUNDS THEREOF
SG188814A1 (en) 2007-10-26 2013-04-30 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
MX2010005099A (es) 2007-11-09 2010-05-27 Novartis Ag Usos de anticuerpos anti-cd40.
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2245065A1 (en) 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
JP5805393B2 (ja) 2008-03-14 2015-11-04 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Ｃｓｆ−１ｒに対する抗体
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
KR20110014141A (ko) 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
WO2009120341A2 (en) 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
CA2716628A1 (en) 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
JP5806110B2 (ja) 2008-04-23 2015-11-10 アムジエン・インコーポレーテツド 中和プロタンパク質コンベルターゼズブチリシンケクシン９型（ｐｃｓｋ９）変形物及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2300040A4 (en) 2008-05-01 2012-06-27 Beth Israel Hospital METHOD AND COMPOSITIONS FOR IMMUNOTHERAPY IN PROSTATE CANCER
CN102027015A (zh) 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
MX2010012518A (es) 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
CN102007147B (zh) 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2735421A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
CA2736198A1 (en) 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL2382722T3 (pl) 2008-12-23 2012-10-31 Koninl Philips Electronics Nv Połączenie komunikacji BCC z komunikacją wcz
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
PT2398498T (pt) 2009-02-17 2018-12-03 Ucb Biopharma Sprl Moléculas de anticorpo tendo especificidade para ox40 humano
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
CA2754743C (en) 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
ES2605228T3 (es) 2009-04-18 2017-03-13 Genentech, Inc. Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40
CA2759146C (en) 2009-04-20 2017-06-13 Kyowa Hakko Kirin Co., Ltd. Agonist anti-cd40 antibody
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
ES2536996T3 (es) 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Anticuerpos biespecíficos de unión a digoxigenina
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
CA2769619C (en) 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
CN102481348A (zh) 2009-08-31 2012-05-30 Ibc药品公司 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme PCSK9 ANTAGONISTS
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
JP2013509191A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
CN102576018A (zh) 2009-10-30 2012-07-11 默沙东公司 Pcsk9免疫测定
US20120208208A1 (en) 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
SI2949670T1 (sl) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
WO2011081164A1 (ja) 2009-12-29 2011-07-07 協和発酵キリン株式会社 抗ｃｄ２７抗体
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
ES2724451T3 (es) 2010-02-04 2019-09-11 Univ Pennsylvania ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
EP2371863A1 (en) 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
SG183947A1 (en) 2010-03-31 2012-10-30 Boehringer Ingelheim Int Anti-cd40 antibodies
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
UY33331A (es) 2010-04-13 2011-10-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
ES2805873T3 (es) 2010-04-16 2021-02-15 Biogen Ma Inc Anticuerpos anti-VLA-4
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
AU2011280969A1 (en) * 2010-07-23 2013-02-07 Trustees Of Boston University Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
PE20180042A1 (es) 2010-08-23 2018-01-09 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
WO2012040207A2 (en) 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
EP2621951A1 (en) 2010-09-29 2013-08-07 Université de Liège Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CN103180342A (zh) 2010-10-27 2013-06-26 皮埃尔法布雷医药公司 用于治疗hiv的抗体
ES2723775T3 (es) 2010-11-08 2019-09-02 Ablynx Nv Polipéptidos que se unen a CXCR2
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CA2820953A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
CN110711248A (zh) 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
JP2014511147A (ja) 2011-02-10 2014-05-12 ロシュ グリクアート アーゲー 改善された免疫療法
WO2012109530A1 (en) 2011-02-11 2012-08-16 Irm Llc Pcsk9 antagonists
US9125893B2 (en) 2011-02-17 2015-09-08 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-CD40 antibody pharmaceutical preparation
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
SG193428A1 (en) 2011-03-31 2013-10-30 Inst Nat Sante Rech Med Antibodies directed against icos and uses thereof
AU2012236479B2 (en) 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
ES2669310T3 (es) * 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
TWI598363B (zh) 2011-04-21 2017-09-11 必治妥美雅史谷比公司 拮抗ｃｄ４０之抗體多肽
CN103619880A (zh) 2011-04-29 2014-03-05 百时美施贵宝公司 Ip-10抗体剂量递增方法
EP2702078B1 (en) 2011-04-29 2018-11-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9732196B2 (en) 2011-05-10 2017-08-15 Sabic Global Technologies B.V. Adhesive for bonding polyimide resins
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
BR112013029893A2 (pt) 2011-05-21 2017-05-30 Macrogenics Inc molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
EP2720718A4 (en) 2011-06-14 2015-01-21 Mayo Foundation ANTI-CD3 THERAPIES
EP2720719A4 (en) 2011-06-15 2015-12-09 Glaxosmithkline Ip No 2 Ltd METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
BR112013031762A2 (pt) 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
RU2014101501A (ru) 2011-06-20 2015-07-27 Дженентек, Инк. Связывающие pcsk9 полипептиды и способы применения
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
MX2014000578A (es) 2011-07-14 2014-04-30 Pfizer Tratamiento con anticuerpos anti-pcsk9.
CA2842169A1 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087363A1 (es) 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
JP6005751B2 (ja) 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マクロファージの活性化の調節
KR102091294B1 (ko) 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
KR102024957B1 (ko) 2011-11-09 2019-09-24 브리스톨-마이어스 스큅 컴퍼니 항-cxcr4 항체를 이용한 혈액 악성종양의 치료
US20130115171A1 (en) 2011-11-09 2013-05-09 Stefan I. McDonough Nav1.7-related assays
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
ES2740358T3 (es) 2012-02-06 2020-02-05 Providence Health & Services Oregon Método de supervisión del tratamiento del cáncer con agonistas de OX40
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR102153374B1 (ko) 2012-03-15 2020-09-10 얀센 바이오테크 인코포레이티드 인간 항-cd27 항체, 방법 및 용도
US20130315913A1 (en) 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
CA2870545A1 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
CN103417967B (zh) 2012-05-15 2017-05-10 中国医学科学院基础医学研究所 Cxcl‑10抑制剂在制备治疗和/或预防肺损伤的药物中的用途
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013172933A1 (en) 2012-05-15 2013-11-21 University Of Southern California Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
RU2636820C2 (ru) 2012-05-17 2017-11-28 Сайон Терапьютикс Инк. Способы и применения ингибиторов пропротеиновой конвертазы субтилизин кексин типа 9(pcsk9)
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2013181087A2 (en) 2012-06-01 2013-12-05 Ibc Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
KR20150018604A (ko) 2012-06-06 2015-02-23 온코메드 파마슈티칼스, 인크. 히포 경로를 조절하는 결합제 및 그의 용도
CN104822704B (zh) 2012-06-14 2020-02-14 医疗生物科学有限公司 针对分化簇3(cd3)的人源化的抗体
EP2895203A4 (en) 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
EP2866830A4 (en) 2012-06-27 2015-12-09 Jyant Technologies ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION
US20140005352A1 (en) 2012-06-29 2014-01-02 Invista North America S.A R.L. Gas scrubber and related processes
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
DE102012013637A1 (de) 2012-07-09 2014-01-09 Iwis Motorsysteme Gmbh & Co. Kg Triebstockplanetengetriebe
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
CA2872195A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR20150047593A (ko) 2012-08-31 2015-05-04 파이브 프라임 테라퓨틱스, 인크. 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌の処置における特異的免疫療法を向上する方法
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
JP2016011258A (ja) 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014065402A1 (ja) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2891000A1 (en) 2012-11-09 2014-05-15 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
CA2892831A1 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
JP6359031B2 (ja) * 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014110258A1 (en) 2013-01-09 2014-07-17 Podack Eckhard R Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN105263958B (zh) 2013-03-13 2019-09-27 比奥阿赛斯技术有限公司 p97片段及其应用
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EA201591754A1 (ru) 2013-03-14 2016-01-29 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к na1.7
US9097712B2 (en) 2013-03-15 2015-08-04 Allied Innovative Systems Llc Flow-through cell counting assay
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
EA201591495A1 (ru) 2013-03-18 2016-05-31 Биосерокс Продактс Б.В. Гуманизированные антитела против cd134 (ox40) и применения указанных антител
BR112015026019A2 (pt) 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
AU2014269287B2 (en) 2013-05-22 2016-08-25 Seoul National University Hospital Anti-TNF-alpha/CXCL10 double-targeting antibody and use thereof
SG11201509618QA (en) 2013-05-24 2015-12-30 Medimmune Llc Anti-b7-h5 antibodies and their uses
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
NZ715896A (en) 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
CN105658666B (zh) 2013-08-01 2021-07-27 鲁汶大学 抗garp蛋白及其用途
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SG11201600171SA (en) 2013-08-02 2016-02-26 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US20160200814A1 (en) 2013-08-22 2016-07-14 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
NZ717534A (en) 2013-08-22 2022-04-29 Council Queensland Inst Medical Res Immunoreceptor modulation for treating cancer and viral infections
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
KR20160055269A (ko) 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
EP3599248A1 (en) 2013-11-06 2020-01-29 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
PT3091991T (pt) 2013-12-13 2020-02-04 Swedish Stromabio Ab Composições imunomodulatórias
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
EP4566623A3 (en) 2013-12-20 2025-08-20 Intervet International B.V. Caninized antibodies
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
DK3089994T3 (da) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
CN113637692A (zh) 2014-01-15 2021-11-12 卡德门企业有限公司 免疫调节剂
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3556775B1 (en) 2014-01-28 2021-11-17 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SI3102595T1 (sl) 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
JP6606505B2 (ja) 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
PE20161571A1 (es) 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
RS59134B1 (sr) 2014-05-13 2019-09-30 Medimmune Ltd Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća
BR112016026993A2 (pt) 2014-05-21 2017-10-31 Kyowa Hakko Kirin Co Ltd combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
CA2951234C (en) 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
EP3171892B1 (en) 2014-07-22 2021-11-24 Apollomics Inc. Anti-pd-1 antibodies
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US10167339B2 (en) 2014-08-04 2019-01-01 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
KR102443258B1 (ko) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
SG11201701039PA (en) 2014-08-14 2017-03-30 Hoffmann La Roche Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
RS59939B1 (sr) * 2014-08-29 2020-03-31 Hoffmann La Roche Kombinovana terapija il-2 varijantom imunocitokina sa ciljanim delovanjem na tumor i antitelima na humani pd-l1
EP3201230B1 (en) 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
EP3201232A1 (en) 2014-10-03 2017-08-09 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
AU2015329982B2 (en) 2014-10-10 2021-05-20 Innate Pharma CD73 blockade
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
US10259874B2 (en) 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
WO2016071448A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Anti-tim3 antibodies and methods of use
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
PT3218406T (pt) 2014-11-10 2021-06-17 Medimmune Ltd Moléculas de ligação específicas para cd73 e seus usos
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
DK4141032T3 (da) 2014-11-20 2024-08-05 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
TW201630937A (zh) 2014-12-22 2016-09-01 戊瑞治療有限公司 用於治療ｐｖｎｓ之抗－ｃｓｆ１ｒ抗體
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
SG10202111844VA (en) 2015-01-09 2021-12-30 Adalta Ltd Cxcr4 binding molecules
CA2974453A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
EP3253413A2 (en) 2015-02-06 2017-12-13 Kadmon Corporation, LLC Immunomodulatory agents
JP6917902B2 (ja) 2015-02-13 2021-08-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
US10259881B2 (en) 2015-02-22 2019-04-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
JP6826055B2 (ja) 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
AU2016235362B2 (en) 2015-03-23 2021-12-16 Jounce Therapeutics, Inc. Antibodies to ICOS
JP6936784B2 (ja) 2015-03-30 2021-09-22 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
DK3277321T3 (da) 2015-04-01 2024-09-02 Anaptysbio Inc Antistoffer, der er rettet mod T-celle-immunglobulin og mucin-protein 3 (TIM-3)
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016171722A1 (en) 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
JP6956639B2 (ja) 2015-05-01 2021-11-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
US10690674B2 (en) 2015-06-03 2020-06-23 Bristol-Myers Squibb Company Anti-GITR antibodies for cancer diagnostics
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP2018521019A (ja) 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
KR20180012873A (ko) 2015-06-24 2018-02-06 에프. 호프만-라 로슈 아게 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체
EP3313880B1 (en) 2015-06-29 2025-08-06 Bristol-Myers Squibb Company Antibodies to cd40
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
CN106331470A (zh) 2015-07-03 2017-01-11 中兴通讯股份有限公司 一种拍摄终端和拍摄方法
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3
EA201890305A1 (ru) 2015-07-15 2018-07-31 Генмаб А/С Гуманизированные или химерные cd3-антитела
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
SI3328419T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
KR20180036996A (ko) 2015-08-04 2018-04-10 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 치료 및 그의 용도 및 방법
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
HRP20241381T1 (hr) 2015-08-11 2024-12-20 WuXi Biologics Ireland Limited Nova anti-pd-1 protutijela
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3344655B1 (en) 2015-09-01 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of lupus nephritis
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
PT3344654T (pt) 2015-09-02 2021-01-26 Immutep Sas Anticorpos anti-lag-3
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
KR102677543B1 (ko) 2015-09-16 2024-06-24 아블렉시스, 엘엘씨 항-cd115 항체
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
KR20230125094A (ko) 2015-09-25 2023-08-28 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
US10981991B2 (en) 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
EP3355920A4 (en) * 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
JP7023233B2 (ja) 2015-10-01 2022-02-21 ポテンザ セラピューティックス インコーポレイテッド 抗ｔｉｇｉｔ抗原結合タンパク質と、その使用方法
RS62258B1 (sr) 2015-10-02 2021-09-30 Hoffmann La Roche Bispecifična antitela specifična za pd1 i tim3
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
JP6771551B2 (ja) 2015-10-15 2020-10-21 ディンフー バイオターゲット カンパニー リミテッド 抗ｏｘ４０抗体及びその応用
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
CN106632674B (zh) 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
WO2017087547A1 (en) 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
CN107406504B (zh) 2015-11-19 2021-04-30 蔡则玲 Ctla-4抗体及其用途
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
CN108350080A (zh) 2015-11-24 2018-07-31 伊莱利利公司 用于癌症的联合疗法
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
BR112018015480A2 (pt) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. proteínas de ligação ao antígeno que se ligam a pd-l1
HK1247214B (zh) 2016-03-04 2019-07-19 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
US10077308B2 (en) 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
SG11201811003PA (en) 2016-06-13 2019-01-30 I Mab Anti-pd-l1 antibodies and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
BR112018076684A2 (pt) 2016-06-29 2019-04-02 Checkpoint Therapeutics, Inc anticorpos pd-l1 específicos e métodos de uso dos mesmos
MA45595A (fr) 2016-07-07 2019-05-15 Iovance Biotherapeutics Inc Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
ES2899036T3 (es) 2016-08-04 2022-03-09 Innovent Biologics Suzhou Co Ltd Nanocuerpo anti-PD-L1 y su uso
JP6925421B2 (ja) 2016-08-05 2021-08-25 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN116492457A (zh) 2016-09-10 2023-07-28 耶达研究与开发有限公司 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤
CA3037230A1 (en) 2016-09-20 2018-03-29 Merck Patent Gmbh Diagnostic anti-pd-l1 antibody and use thereof
RU2770590C2 (ru) 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты
CN110392694B (zh) 2016-11-02 2023-08-04 震动疗法股份有限公司 针对pd-1的抗体及其用途
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
JP7128529B2 (ja) 2016-12-23 2022-08-31 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
JP7105238B2 (ja) 2017-01-18 2022-07-22 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用
IL322509A (en) 2017-03-09 2025-10-01 Genmab As Antibodies against PD-L1
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018195226A1 (en) 2017-04-18 2018-10-25 R-Pharm Overseas, Inc. Anti-pd-l1 antibody and use thereof
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
HUE068059T2 (hu) * 2018-09-17 2024-12-28 Gi Innovation Inc Il-2 fehérjét és CD80 fehérjét tartalmazó fúziós fehérje és annak felhasználása
US10442866B1 (en) 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof

Also Published As

Publication number Publication date
US12209128B2 (en) 2025-01-28
TWI640536B (zh) 2018-11-11
SG11201810509PA (en) 2018-12-28
AU2017281830B2 (en) 2023-04-06
CA3026474A1 (en) 2017-12-28
IL263834A (en) 2019-01-31
CA3026477A1 (en) 2017-12-28
JP7261379B2 (ja) 2023-04-20
WO2017220990A1 (en) 2017-12-28
RU2018147413A3 (OSRAM) 2020-07-21
EP3471754A1 (en) 2019-04-24
TW201803905A (zh) 2018-02-01
RU2018147413A (ru) 2020-07-21
BR112018076281A2 (pt) 2019-03-26
TWI784957B (zh) 2022-12-01
WO2017220988A1 (en) 2017-12-28
EP3471753A1 (en) 2019-04-24
AU2017281830A1 (en) 2018-12-13
IL263834B2 (en) 2024-01-01
TW201803904A (zh) 2018-02-01
JP2020511932A (ja) 2020-04-23
JP7595618B2 (ja) 2024-12-06
JP2024167230A (ja) 2024-12-03
BR112018076260A2 (pt) 2019-03-26
US20240343810A1 (en) 2024-10-17
ZA201900353B (en) 2021-09-29
RU2018147423A3 (OSRAM) 2020-10-16
JP2022166172A (ja) 2022-11-01
NZ748710A (en) 2025-07-25
CN109475603B (zh) 2023-06-13
KR102531889B1 (ko) 2023-05-17
CN109475602B (zh) 2023-05-16
US20230312720A1 (en) 2023-10-05
KR102379464B1 (ko) 2022-03-29
TW201811820A (zh) 2018-04-01
RU2756236C2 (ru) 2021-09-28
KR20190032355A (ko) 2019-03-27
RU2018147423A (ru) 2020-07-21
JP2022180438A (ja) 2022-12-06
CN109475602A (zh) 2019-03-15
WO2017220988A9 (en) 2018-02-15
NZ789594A (en) 2025-07-25
KR20190030208A (ko) 2019-03-21
US20240360218A1 (en) 2024-10-31
RU2769282C2 (ru) 2022-03-30
CN116903741A (zh) 2023-10-20
US20210380699A1 (en) 2021-12-09
WO2017220990A9 (en) 2018-03-01
WO2017220989A8 (en) 2018-12-27
IL263834B1 (en) 2023-09-01
JP2019528083A (ja) 2019-10-10
CN109475603A (zh) 2019-03-15
TWI793162B (zh) 2023-02-21
TW201900680A (zh) 2019-01-01
JP7461741B2 (ja) 2024-04-04
WO2017220989A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MX2018016364A (es) Anticuerpos anti-pd-l1.
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2019000628A1 (es) Anticuerpos anti-pd-1 y sus usos.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
EP4406554A3 (en) Anti-cd3 antibody formulations
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
MX388181B (es) Anticuerpos anti-pd-1.
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
JOP20170170A1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2023005879A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
MX385853B (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr.
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
MX390385B (es) Anticuerpos anti-pd-l1.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.